The product is bioequivalent and therapeutically equivalent to Vascepa (Reference Listed Drug) and will be produced in Bengaluru.
SEBI mandates that promoters cannot hold more than 75% of a company's stake, and Glenmark has until August 2024 to meet this requirement
It was mentioned that at the end of the inspection, a Form 483 was given with one procedural observation.
Tyvalzi™ is designed to treat cerebral ischemic stroke and is a first-in-class drug developed by Pharmazz for potential global use
Bajaj Healthcare's Savli plant is primarily involved in manufacturing Active Pharmaceutical Ingredients (API)
Torrent Pharma's interest stems from its desire to acquire a company with metrics more than 2.3 times its revenue, double its profit, and 1.46 times its market value
Tobramycin Ophthalmic Solution is used for the treatment of bacterial infections of the eye.
Aurobindo Pharma announced the product's launch in September 2023
The product will be available from September 2023 onwards.
In April-June 2023-24, the pharmaceutical company declared a net profit of Rs 520.5 crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
